- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Density estimation.
Displaying page 1 of 1.
EudraCT Number: 2017-002723-16 | Sponsor Protocol Number: PREMIVER | Start Date*: 2018-04-20 |
Sponsor Name:Universitaetsklinikum Tuebingen | ||
Full Title: Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial | ||
Medical condition: In spite of remarkable progress over the last 15 years, malaria continues to be a major public health problem in the developing world with an estimated 214 million cases and 438.000 deaths in 2014.... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001381-15 | Sponsor Protocol Number: RICH-ART | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Sahlgrenska University Hospital Västra Götalandsregionen | |||||||||||||
Full Title: Radiation Induced Cystits treated with Hyperbaric Oxygen. A Randomized controlled Trial | |||||||||||||
Medical condition: Radiation Cystitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002697-45 | Sponsor Protocol Number: ACT15378 | Start Date*: 2019-03-04 | ||||||||||||||||
Sponsor Name:Sanofi-aventis recherche & developpement | ||||||||||||||||||
Full Title: Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Year... | ||||||||||||||||||
Medical condition: Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination with Chemotherapy in Pediatric Patients from 28 Days to Less than 18 Year... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) NO (Completed) FI (Completed) DK (Completed) FR (Completed) NL (Completed) PT (Completed) BE (Completed) DE (Completed) CZ (Completed) GR (Completed) Outside EU/EEA IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004046-15 | Sponsor Protocol Number: TKA4 | Start Date*: 2013-07-03 | |||||||||||
Sponsor Name:ORtopædkirurgisk Forskningsenhed, Aarhus Universitetshospital | |||||||||||||
Full Title: A 4-way randomized double-blinded migration (RSA), bone density (DXA), and biomarker study assessing adaptive bone changes and implant fixation and longevity of the new Regenerex Porous Titanium Ti... | |||||||||||||
Medical condition: Osteoarthritis in the knee treated with cementless total knee arthroplasty | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003827-37 | Sponsor Protocol Number: 20110109 | Start Date*: 2012-01-06 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-term Tolerability and Durable Efficacy of AMG 145 on LDL-C in Hyperlipidemic Subjects | |||||||||||||
Medical condition: Hyperlipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) BE (Completed) AT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005033-22 | Sponsor Protocol Number: UOL001362 | Start Date*: 2019-06-19 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: In patients taking Protease Inhibitors does switching to a Bictegravir, Tenofovir Alafenamide and Emtricitabine combination, reduce cardiovascular risk: An open-label, randomised, serial CT pilot s... | |||||||||||||
Medical condition: Human immunodeficiency virus (HIV) and cardiovascular disease (CVD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003915-11 | Sponsor Protocol Number: CarniValI (Uni-Koeln-1107) | Start Date*: 2009-09-24 | |||||||||||
Sponsor Name:University of Utah | |||||||||||||
Full Title: Phase I/II Trial of Valproic Acid and Carnitine in Infants with Spinal Muscular Atrophy Type I (CARNI-VAL Type I) | |||||||||||||
Medical condition: Spinal Muscular Atrophy Type I in infants | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001039-29 | Sponsor Protocol Number: GO40515 | Start Date*: 2019-02-26 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH CHOP OR ... | |||||||||||||
Medical condition: B-Cell Non-Hodgkin Lymphoma (B-cell NHL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) AT (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003376-49 | Sponsor Protocol Number: MDCO-PCS-16-02 | Start Date*: 2017-06-20 | |||||||||||
Sponsor Name:The Medicines Company | |||||||||||||
Full Title: An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects with Homozygous Familial Hypercholesterolemia | |||||||||||||
Medical condition: Homozygous Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005782-59 | Sponsor Protocol Number: 08/0136 | Start Date*: 2010-09-29 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: ARISTOTLE - A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer. | ||||||||||||||||||
Medical condition: Locally advanced rectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000191-41 | Sponsor Protocol Number: GC28210 | Start Date*: 2012-06-19 | |||||||||||
Sponsor Name:GENENTECH, Inc. | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF MPSK3169A IN PATIENTS WITH CORONARY HEART DISEASE OR HIGH RISK OF CORONARY HEART DISEASE | |||||||||||||
Medical condition: Coronary Heart Disease or High Risk of Coronary Heart Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002302-46 | Sponsor Protocol Number: IMIB-TCIM/ELAII-2019-01 | Start Date*: 2019-10-23 |
Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia | ||
Full Title: Phase II clinical trial of intramuscular infusion of autologous bone marrow stem cells in patients with amyotrophic lateral sclerosis | ||
Medical condition: Amyotrophic Lateral Sclerosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003177-58 | Sponsor Protocol Number: SPIOMET4HEALTH | Start Date*: 2022-05-12 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu (FSJD) | |||||||||||||
Full Title: A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIO... | |||||||||||||
Medical condition: Polycystic Ovary Syndrome (PCOS) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001425-32 | Sponsor Protocol Number: 14SM2359 | Start Date*: 2015-01-13 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: RIVER - Research In Viral Eradication of HIV Reservoirs, A two-arm (proof of concept) randomised phase II trial | |||||||||||||
Medical condition: HIV Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001088-26 | Sponsor Protocol Number: MN42928 | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | |||||||||||||
Full Title: SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION | |||||||||||||
Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005088-30 | Sponsor Protocol Number: STOP-LEUKEMIA | Start Date*: 2021-03-26 | |||||||||||
Sponsor Name:Kirsten Grønbæk | |||||||||||||
Full Title: STOP-LEUKEMIA: A pilot study of metformin as a leukemia-preventive drug in patients with CCUS or LR-MDS | |||||||||||||
Medical condition: Clonal cytopenia of undetermined significance (CCUS) and lower-risk myelodysplastic syndrome (LR-MDS). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006439-12 | Sponsor Protocol Number: INSIGHT001:STARTDAIDSID#10619 | Start Date*: 2009-05-25 |
Sponsor Name:Regents of the University of Minnesota | ||
Full Title: Strategic Timing of AntiRetroviral Treatment(START) | ||
Medical condition: HIV Infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) FI (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) GR (Completed) IT (Completed) SE (Completed) PT (Completed) IE (Completed) EE (Completed) NO (Completed) AT (Completed) CZ (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
